Kenneth Zuerblis

Kenneth Zuerblis

Director/Board Member at RESVERLOGIX CORP.

Net worth: 34 203 $ as of 30/05/2026

66 year
Health Technology
Commercial Services
Consumer Services

Profile

Mr. Kenneth J.
Zuerblis
, CPA, is an Independent Director at Zenith Capital Corp.
(Alberta) and an Independent Director at Resverlogix Corp.
He is on the Board of Directors at Lirum Therapeutics, Inc., Zenith Capital Corp.
(Alberta) and Resverlogix Corp.
Mr. Zuerblis was previously employed as a Chief Financial Officer, Treasurer & Executive VP by Savient Pharmaceuticals, Inc., an Independent Director by Immunomedics, Inc., a Chief Financial Officer & Senior Vice President by ImClone Systems, Inc., a Chief Financial Officer by Enzon Pharmaceuticals, Inc., and a Controller by KPMG LLP.
He also served on the board at Stemline Therapeutics, Inc., XTL Biopharmaceuticals Ltd. and New Jersey Technology Council.
He received his undergraduate degree from Seton Hall University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
18/05/2026 263,870 ( 0.17% ) 26 387 $ 30/01/2026
01/01/2026 107,062 ( 0.03% ) 7 816 $ 30/05/2026

Kenneth Zuerblis active positions

CompaniesPositionStart
RESVERLOGIX CORP. Director/Board Member 28/09/2010
ZENITH CAPITAL CORP. Director/Board Member 09/04/2013
LIRUM THERAPEUTICS, INC. Director/Board Member 30/04/2023

Former positions of Kenneth Zuerblis

CompaniesPositionEnd
STEMLINE THERAPEUTICS, INC. Director/Board Member 09/06/2020
SAVIENT PHARMACEUTICALS INC Director of Finance/CFO 30/04/2012
IMMUNOMEDICS, INC. Director/Board Member 07/03/2012
Director of Finance/CFO 31/12/2008
XTL BIOPHARMACEUTICALS LTD. Director/Board Member 31/12/2008
See the detail of Kenneth Zuerblis's experience

Training of Kenneth Zuerblis

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

77

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Commercial Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Kenneth Zuerblis